Therefore, even though the potential of LIGHT as an immunotherapeutic anticancer agent has been explored for over a decade [29] in both primary and metastatic settings using various delivery systems, the specifics of pancreatic cancer would add additional difficulty to the targeting of the LIGHT-armed vector. Here, TNFSF14 is linked to familial pancreatic carcinoma.